WuXi XDC Named Best CDMO Winner at 2024 World ADC Awards
The Californer/10296808

Trending...
SHANGHAI and SAN DIEGO, Nov. 7, 2024 ~ San Diego, California - WuXi XDC Cayman Inc. ("WuXi XDC"), a global leader in Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in antibody-drug conjugates (ADCs) and other bioconjugates (XDCs), has been named the winner of the "Best CDMO" at the World ADC Awards 2024 for the second consecutive year. The company's consistent recognition at the World ADC Awards over the past three years, including being named the winner of "Best CDMO" in 2023 and "Best CMO Runner-up" in 2022, highlights its expertise and technical strength in driving innovation in the global ADC industry.

The prestigious award was presented at the World ADC San Diego conference, which brings together key industry experts, breakthrough technologies, and forward-thinking collaborations. The annual event recognizes outstanding achievements by teams, projects, technologies, and individuals in the global ADC industry. This year's conference highlighted the latest advancements in ADCs and XDCs from research through to commercialization.

Dr. Jimmy Li, CEO of WuXi XDC expressed his pride in winning this prestigious award for two consecutive years. He stated that it is a reflection of their team's relentless dedication to innovation and excellence. The recognition also underscores the significant trust their clients place in them as a global leader in the ADC industry.

More on The Californer
WuXi XDC's mission is to accelerate and transform the discovery, development, and manufacturing of bioconjugates through a comprehensive open-access platform. They aim to enable their global healthcare partners and benefit patients worldwide by providing state-of-the-art technologies and integrated solutions.

The company won the Best CDMO Winner award for its integrated one-stop CRDMO platform that significantly reduces timelines and mitigates risks associated with ADC development and manufacturing. With WuXi XDC's integrated solutions, they have shortened the DNA-to-IND timeline for ADCs to 15 months or less, cutting down the conventional timeline to enter clinical trials by almost half. Additionally, they accelerate the development to Biologics License Application (BLA) within 24-36 months.

WuXi XDC's success is attributed to their profound expertise in ADC technology, extensive experience in handling complex bioconjugates, and a truly integrated approach that unifies discovery, development, and manufacturing. By leveraging cutting-edge technologies and a global team of industry experts, WuXi XDC ensures seamless interdisciplinary collaboration, minimizing risks and maximizing efficiency throughout the ADC development process.

More on The Californer
Their all-in-one manufacturing strategy integrates all four key phases of ADC production - mAb intermediate, linker-payload, drug substance, drug product - into one single site. This approach ensures seamless coordination and the highest product quality, making WuXi XDC a reliable partner for clients seeking to advance their ADC/XDC programs efficiently and effectively. This combination of cutting-edge technology, industry experience, and integrated solutions distinguishes WuXi XDC as a leader in the evolving ADC landscape.

According to their 2024 interim report, WuXi XDC's leadership in the ADC field is demonstrated by its expanding client base of 419 clients globally. Notably, 13 of the top 20 global pharmaceutical companies (ranked by 2023 revenue) have chosen WuXi XDC as their trusted partner. This reflects the high level of confidence placed in the company's expertise and capabilities.

The recognition from the World ADC Awards highlights WuXi XDC's relentless pursuit of excellence in delivering comprehensive service solutions to global clients. As a leading CRDMO in ADC and bioconjugates, they strive to remain at the forefront of innovation and empower clients worldwide to accelerate the development of transformative therapies for patients worldwide.
Filed Under: Business
Show All News | Report Violation

0 Comments

Latest on The Californer